He Bang-Shun, Xu Tao, Pan Yu-Qin, Wang Han-Jin, Cho William C, Lin Kang, Sun Hui-Ling, Gao Tian-Yi, Wang Shu-Kui
General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Oncotarget. 2016 Dec 20;7(51):84872-84882. doi: 10.18632/oncotarget.12744.
Polymorphisms in nucleotide excision repair (NER) pathway genes are associated with the risk of breast cancer, but the relevance of these associations appeared to vary according to the ethnicity of the subjects. To systemically evaluate the potential associations between NER polymorphisms and breast cancer risk in a Chinese population, we carried out a case-control study on 450 breast cancer patients and 430 healthy controls. Sequenom MassARRAY was used for genotyping, and immunohistochemistry was performed to detect estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression in tumor tissue. Our results showed that ERCC1 rs11615 (additive model: ORadjusted: 1.36, 95% CI: 1.08-1.71, p = 0.009), XPC rs2228000 (additive model: ORadjusted: 1.39, 95% CI: 1.13-1.72, p = 0.002) and ERCC2/XPD rs50872 (additive model: ORadjusted: 1.32, 95% CI: 1.04-1.67, p = 0.021) were associated with an increased risk of breast cancer. Stratified analysis revealed three polymorphisms (rs11615, rs1800975, and rs50872) to be associated with breast cancer in menopausal females. Three polymorphisms were associated with specific breast cancer grades (rs11615 with grade 3, rs2228000 and rs50872 with grade 1-2). Two polymorphisms (rs2228001 and rs50872) were associated with the risk of breast cancer with negative lymph node involvement. rs1800975 and rs50872 were associated with the risk of ER- and PR- breast cancer, whereas rs11615 was associated with the risk of ER+ and PR+ breast cancer. We found that carriers of the T allele of ERCC1 rs11615, XPC rs2228000 and rs50872, particularly in postmenopausal females, have an increased risk of breast cancer.
核苷酸切除修复(NER)途径基因的多态性与乳腺癌风险相关,但这些关联的相关性似乎因受试者的种族而异。为了系统评估中国人群中NER多态性与乳腺癌风险之间的潜在关联,我们对450例乳腺癌患者和430例健康对照进行了一项病例对照研究。使用Sequenom MassARRAY进行基因分型,并进行免疫组织化学检测肿瘤组织中雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER-2)的表达。我们的结果显示,ERCC1 rs11615(相加模型:校正后OR:1.36,95%CI:1.08 - 1.71,p = 0.009)、XPC rs2228000(相加模型:校正后OR:1.39,95%CI:1.13 - 1.72,p = 0.002)和ERCC2/XPD rs50872(相加模型:校正后OR:1.32,95%CI:1.04 - 1.67,p = 0.021)与乳腺癌风险增加相关。分层分析显示,三种多态性(rs11615、rs1800975和rs50872)与绝经后女性的乳腺癌相关。三种多态性与特定的乳腺癌分级相关(rs11615与3级相关,rs2228000和rs50872与1 - 2级相关)。两种多态性(rs2228001和rs50872)与淋巴结阴性的乳腺癌风险相关。rs1800975和rs50872与ER-和PR-乳腺癌风险相关,而rs11615与ER+和PR+乳腺癌风险相关。我们发现,ERCC1 rs11615、XPC rs2228000和rs50872的T等位基因携带者,特别是绝经后女性,患乳腺癌的风险增加。